NASDAQ:OTLK Oncobiologics Q3 2025 Earnings Report $0.57 -0.05 (-8.34%) Closing price 09/30/2026 04:00 PM EasternExtended Trading$0.59 +0.02 (+2.88%) As of 04:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Oncobiologics EPS ResultsActual EPS-$0.44Consensus EPS -$0.42Beat/MissMissed by -$0.02One Year Ago EPSN/AOncobiologics Revenue ResultsActual Revenue$1.51 millionExpected Revenue$1.66 millionBeat/MissMissed by -$157.00 thousandYoY Revenue GrowthN/AOncobiologics Announcement DetailsQuarterQ3 2025Date8/14/2025TimeBefore Market OpensConference Call DateThursday, August 14, 2025Conference Call Time12:00AM ETUpcoming EarningsOncobiologics' Q4 2026 earnings is estimated for Friday, December 18, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, December 17, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Oncobiologics Earnings HeadlinesOutlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-DemandSeptember 11, 2026 | globenewswire.comOutlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect SegmentSeptember 10, 2026 | globenewswire.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account. | Profits Run (Ad)Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™August 27, 2026 | globenewswire.comOutlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand ConferenceAugust 27, 2026 | globenewswire.comOutlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call TranscriptAugust 14, 2026 | seekingalpha.comSee More Oncobiologics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Oncobiologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oncobiologics and other key companies, straight to your email. Email Address About OncobiologicsOncobiologics (NASDAQ:OTLK), now known as Outlook Therapeutics, Inc. (NASDAQ: OTLK), is a biopharmaceutical company focused on developing and commercializing ophthalmic medicines. The company specializes in biologic therapies intended to address diseases affecting the eye, with an emphasis on retinal disorders. The company’s lead product is ONS-5010, an ophthalmic formulation of bevacizumab developed for intravitreal treatment of wet age-related macular degeneration and other retinal conditions. The product is marketed in the United States under the brand name LYTENAVA. Outlook Therapeutics has also evaluated the therapy in additional retinal diseases, including diabetic macular edema and retinal vein occlusion. Founded as Oncobiologics, the company changed its name to Outlook Therapeutics as it shifted its strategic focus toward ophthalmic biologics. Based in the United States, Outlook Therapeutics has pursued regulatory approvals and commercialization opportunities in the U.S. and international markets. The company’s leadership includes Russell C. Katz, who has served as chief executive officer.View Oncobiologics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?CarMax Just Gave Investors a Better Reason to Believe in the TurnaroundArhaus Has New Momentum—Could Other Furniture Stocks Be Next?Bernstein Downgrades 3 Cybersecurity Stocks: How Concerned Should Investors Be?Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
